Reuters logo
BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy
2017年10月16日 / 中午12点12分 / 1 个月内

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

Oct 16 (Reuters) - Aimmune Therapeutics Inc:

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics Inc - ‍regeneron will sponsor trial, with Aimmune to provide clinical supply of AR101 and food challenge materials​

* Aimmune Therapeutics Inc - ‍clinical collaboration will include formation of an Aimmune-Regeneron/Sanofi joint development committee​

* Aimmune Therapeutics Inc - ‍planned phase 2 clinical trial to study AR101 is expected to begin in 2018​

* Aimmune Therapeutics Inc - ‍trial design will test potential to achieve sustained unresponsiveness to peanut following treatment​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below